Accelerating Innovation at Leica Biosystems

DANAHER CORPORATION Forecasted Core Sales Growth and Core Sales Growth Including Cytiva ¹ Core sales growth (non-GAAP) Impact of Cytiva sales growth (net of divested product lines) +Low single-digit Core sales growth including Cytiva (non-GAAP) ~+20% % Change Year Ending December 31, 2021 (Estimated) vs. Comparable 2020 Period Total Company +High-teens Life Sciences Segment +High-teens +Low single / mid single-digit ~+>20% 1 We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue. 2

View entire presentation